Quanterix Corp logo

Quanterix Corp(QTRX)

upturn advisory logo
ADVISORIES YOU CAN VERIFY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$3.07
09/18/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close

Advisory Performance History (Simulated)Advisory Performance History info

Upturn Advisory & Investor View for QTRX

09/18/2026: QTRX (1-star) is currently NOT-A-BUY. Pass it for now.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -69.24%
Avg. Invested days 19
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 09/18/2026

Upturn Scorecard

Upturn Star Rating

QTRX receives a 2-star rating, supported by available scored pillars. The rating is constrained by weak unit economics, weak price momentum, and limited analyst upside.

Company Fundamentals

QTRX has moderate overall fundamentals (3 stars), with soft financial health, soft growth momentum, and strong ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-178.1%), soft cash generation (FCF margin -57.6%), moderate revenue growth (+2.4%).

Financial Health Rating

QTRX's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 32.8%). Operating efficiency is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

Revenue growth is QTRX's strongest growth driver at +2.4% FY2025 versus FY2024 (moderate, 3 stars). By comparison, while earnings growth (-178.1%, negative) and free-cash-flow growth (-107.2%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

Institutional ownership is 71.2% and approximately 80.4% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 6.33% supports management-shareholder alignment.

Top 5 Institutional Investors

Arnhold & S. Bleichroeder Advisers, LLC 11.64%
Ameriprise Financial Inc 7.49%
Blue Water Life Science Advisors, LLC 7.35%
BlackRock Inc 6.93%
Portolan Capital Management, LLC 6.23%

Unit Economics (Per $1K Revenue)

QTRX generates approximately $467 of gross profit, $-792 of operating income, and $-576 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Strong cash conversion and healthy margins support the rating, although capital efficiency remains below the highest tier.

Economic Dimensions

Effective Tax Rate: 4.56%

Quantitative Style Profile

QTRX has a liquid profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedSmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 145.19M USD
Price to earnings Ratio -
1Y Target Price 3
Price to earnings Ratio -
1Y Target Price 3
Volume (30-day avg) 1.0M shares
Beta 1.04
52 Weeks Range 2.15 - 8.77
Updated Date 09/19/2026
52 Weeks Range 2.15 - 8.77
Updated Date 09/19/2026
Dividends yield (FY) -
Basic EPS (TTM) -2.62

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Advertisement

Valuation

Trailing PE -
Forward PE -
Enterprise Value 84.57M
Price to Sales(TTM) 0.95
Enterprise Value 84.57M
Price to Sales(TTM) 0.95
Enterprise Value to Revenue 0.55
Enterprise Value to EBITDA -1.49
Shares Outstanding 47.29M
Shares Floating 38.01M
Shares Outstanding 47.29M
Shares Floating 38.01M
Percent Insiders 6.33
Percent Institutions 71.2

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

About Quanterix Corp

Exchange NASDAQ
Headquarters Billerica, MA, United States
IPO Launch date 2017-12-07
President, CEO & Director Mr. Everett V. Cunningham
Sector Healthcare
Industry Medical Devices
Full time employees 450
Full time employees 450

Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research and clinical laboratory testing services, including research and clinical trial testing, and lucent diagnostic services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and sales force and distributors. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.